Why BioCryst Pharmaceuticals, Inc.’s (BCRX) Stock Is Down 7.79%
As of Thursday, September 10, BioCryst Pharmaceuticals, Inc.’s BCRX share price has dipped by 7.79%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: BioCryst Pharmaceuticals, Inc. (BCRX)
BioCryst Pharmaceuticals, Inc. BCRX
$8.12
-0.17
-2.05%
September 11, 2026 4:00:00 PM
EST
Volume: 3,585,854
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Commentary & Analysis
Why BioCryst Pharmaceuticals, Inc.’s (BCRX) Stock Is Down 7.73%
As of Tuesday, September 08, BioCryst Pharmaceuticals, Inc.’s BCRX share price has dipped by 7.73%, which has investors questioning if this is right time to buy.Jenna Brashear
Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Xencor, Inc. Stock?
Learn more about whether BioCryst Pharmaceuticals, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
4 Undervalued Biotechnology Stocks for Friday, August 14
Discover the top 4 undervalued Biotechnology stocks for Friday, August 14 based on AAII’s Stock Grades.Tudor Pop
Why BioCryst Pharmaceuticals, Inc.’s (BCRX) Stock Is Down 6.37%
As of Thursday, August 13, BioCryst Pharmaceuticals, Inc.’s BCRX share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,074.9 | $269.3 | 54% |
|
| Shares Out (Mil) | 265.2 | 54.0 | 81% |
|
| Institutional Ownership | 99.0% | 93.0% | 84% |
|
| Float (Mil) | 222.3 | 42.2 | 76% |
|
| Beta | 0.56 | 0.95 | 32% |
|
| Avg Daily Volume (000s) | 4,285 | 473 | 92% |
|
| Price Change (52-week) |
1.4% | 55.9% | 49% |
|
| Growth | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 117.9% | 14.1% | 99% |
|
| Net Income (5yr) | 28.1% | (10.1%) | 83% |
|
| EPS (5yr) | 25.4% | 15.7% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.7%) | (15.6%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | $0.115 | $0.745 | $0.940 | |
| Month Ago EPS | $0.115 | $0.745 | $0.940 | |
| # Rev Up | 0 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.105 | $0.565 | $0.680 | |
| Year/Year Chg | (61.7%) | (38.4%) | 3.7% | |
| Financials | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $941 | $37 | 49% |
|
| Net Income (TTM) (Mil) | ($385) | ($43) | 4% |
|
| EPS (TTM) | ($1.676) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | $376 | ($31) | 67% |
|
| Net Cash Flow (TTM) (Mil) | $51 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $790 | $4 | 63% |
|
| Enterprise Value (Q1) (Mil) | $3,062 | $182 | 54% |
|
| Valuation | BCRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.62 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.4% | 67.6% | 87% |
|
| Net Margin | (40.9%) | (73.5%) | 13% |
|
| ROA | (75.8%) | (47.9%) | 8% |
|
| ROE | 87.8% | (55.0%) | 96% |
|
| Liabilities to Assets | 181.4% | 29.5% | 99% |
|
| F-Score | 5 | 3 | 50% |
|
BioCryst Pharmaceuticals, Inc. did not pass any screens on 9/11/2026.
